Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects

Trial Profile

Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 14 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 04 Jun 2013 Planned number of patients changed from 666 to 667 as reported by European Clinical Trials Database.
    • 27 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top